Stock Track | Verastem Plummets 20.81% as Q3 Net Loss Widens to $98.5 Million Despite Revenue Beat

Stock Track11-04

Verastem (NASDAQ: VSTM) shares plummeted 20.81% in Tuesday's pre-market trading session following the release of its third-quarter 2025 financial results. The oncology-focused biopharmaceutical company reported a significant widening of its net loss, overshadowing a better-than-expected revenue performance.

The company reported a GAAP net loss of $98.5 million, or $1.35 per share, for Q3 2025, a substantial increase from the $24.0 million loss, or $0.60 per share, in the same period last year. This widening loss appears to be the primary driver behind the stock's sharp decline. On a non-GAAP basis, the adjusted net loss was $39.4 million, or $0.54 per share, which beat analyst estimates of a $0.64 loss per share but still represented a decline from the $0.88 loss per share in Q3 2024.

Despite the disappointing bottom line, Verastem's Q3 net product revenue reached $11.2 million, marking a successful product launch and beating the analyst consensus estimate of $5.659 million by 98.64%. However, investors seem more concerned with the company's rising expenses, as operating expenses for the quarter increased to $51.957 million, primarily due to higher research and development costs. The company's cash runway is expected to extend into the second half of 2026, which may provide some reassurance to long-term investors, but the immediate focus on widening losses has triggered a significant sell-off in the stock.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1111971005?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 23:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111971005","market":"sg","top_or_hot":-1,"title":"Stock Track | Verastem Plummets 20.81% as Q3 Net Loss Widens to $98.5 Million Despite Revenue Beat","media":"Stock Track","content":"<p>Verastem (NASDAQ: VSTM) shares plummeted 20.81% in Tuesday's pre-market trading session following the release of its third-quarter 2025 financial results. The oncology-focused biopharmaceutical company reported a significant widening of its net loss, overshadowing a better-than-expected revenue performance.</p>\n\n<p>The company reported a GAAP net loss of $98.5 million, or $1.35 per share, for Q3 2025, a substantial increase from the $24.0 million loss, or $0.60 per share, in the same period last year. This widening loss appears to be the primary driver behind the stock's sharp decline. On a non-GAAP basis, the adjusted net loss was $39.4 million, or $0.54 per share, which beat analyst estimates of a $0.64 loss per share but still represented a decline from the $0.88 loss per share in Q3 2024.</p>\n\n<p>Despite the disappointing bottom line, Verastem's Q3 net product revenue reached $11.2 million, marking a successful product launch and beating the analyst consensus estimate of $5.659 million by 98.64%. However, investors seem more concerned with the company's rising expenses, as operating expenses for the quarter increased to $51.957 million, primarily due to higher research and development costs. The company's cash runway is expected to extend into the second half of 2026, which may provide some reassurance to long-term investors, but the immediate focus on widening losses has triggered a significant sell-off in the stock.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Verastem Plummets 20.81% as Q3 Net Loss Widens to $98.5 Million Despite Revenue Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Verastem Plummets 20.81% as Q3 Net Loss Widens to $98.5 Million Despite Revenue Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-04 23:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Verastem (NASDAQ: VSTM) shares plummeted 20.81% in Tuesday's pre-market trading session following the release of its third-quarter 2025 financial results. The oncology-focused biopharmaceutical company reported a significant widening of its net loss, overshadowing a better-than-expected revenue performance.</p>\n\n<p>The company reported a GAAP net loss of $98.5 million, or $1.35 per share, for Q3 2025, a substantial increase from the $24.0 million loss, or $0.60 per share, in the same period last year. This widening loss appears to be the primary driver behind the stock's sharp decline. On a non-GAAP basis, the adjusted net loss was $39.4 million, or $0.54 per share, which beat analyst estimates of a $0.64 loss per share but still represented a decline from the $0.88 loss per share in Q3 2024.</p>\n\n<p>Despite the disappointing bottom line, Verastem's Q3 net product revenue reached $11.2 million, marking a successful product launch and beating the analyst consensus estimate of $5.659 million by 98.64%. However, investors seem more concerned with the company's rising expenses, as operating expenses for the quarter increased to $51.957 million, primarily due to higher research and development costs. The company's cash runway is expected to extend into the second half of 2026, which may provide some reassurance to long-term investors, but the immediate focus on widening losses has triggered a significant sell-off in the stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VSTM","symbol_name":"Verastem","start_time":0,"source_url":"","article_id":"1111971005","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111971005","pubTimestamp":1762269921,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Verastem (NASDAQ: VSTM) shares plummeted 20.81% in Tuesday's pre-market trading session following the release of its third-quarter 2025 financial results. The oncology-focused biopharmaceutical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VSTM":"Verastem"},"translate_title":"个股追踪|Verastem暴跌20.81%，第三季度净亏损扩大至9850万美元，尽管营收超预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VSTM":1},"content_text":"Verastem (NASDAQ: VSTM) shares plummeted 20.81% in Tuesday's pre-market trading session following the release of its third-quarter 2025 financial results. The oncology-focused biopharmaceutical company reported a significant widening of its net loss, overshadowing a better-than-expected revenue performance.\nThe company reported a GAAP net loss of $98.5 million, or $1.35 per share, for Q3 2025, a substantial increase from the $24.0 million loss, or $0.60 per share, in the same period last year. This widening loss appears to be the primary driver behind the stock's sharp decline. On a non-GAAP basis, the adjusted net loss was $39.4 million, or $0.54 per share, which beat analyst estimates of a $0.64 loss per share but still represented a decline from the $0.88 loss per share in Q3 2024.\nDespite the disappointing bottom line, Verastem's Q3 net product revenue reached $11.2 million, marking a successful product launch and beating the analyst consensus estimate of $5.659 million by 98.64%. However, investors seem more concerned with the company's rising expenses, as operating expenses for the quarter increased to $51.957 million, primarily due to higher research and development costs. The company's cash runway is expected to extend into the second half of 2026, which may provide some reassurance to long-term investors, but the immediate focus on widening losses has triggered a significant sell-off in the stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1111971005","isCrawlerRequest":true}